Here are what the editors at HealthDay consider to be the most important developments in Urology for November 2006. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Lower-Dose Botox Effective for Detrusor Overactivity
WEDNESDAY, Nov. 29 (HealthDay News) -- Botulinum A toxin can be used to treat patients with detrusor overactivity that is refractory to anticholinergics and 100 U injections seem to be as effective as higher doses at controlling incontinence, according to a report in the November issue of Urology.
Abstract
Full Text (subscription or payment may be required)
Radiofrequency Ablation of Renal Tumors Can Fail
TUESDAY, Nov. 28 (HealthDay News) -- Radiofrequency ablation of renal tumors without resection can sometimes be ineffective and lead to tumor progression and the formation of renocolic fistulas, according to two cases reported in the November issue of Urology.
Abstract
Full Text (subscription or payment may be required)
Half of Patients Have Morbidity After Brachytherapy
FRIDAY, Nov. 24 (HealthDay News) -- Although more than half of men who have prostate brachytherapy experience complications, 14 percent requiring invasive procedures, the number of invasive procedures has fallen over time, according to study findings published in the Nov. 20 issue of the Journal of Clinical Oncology. The findings suggest that experience with the technique has improved outcome.
Abstract
Full Text (subscription or payment may be required)
Bacterial Biofilms Form on Catheters in Hours
THURSDAY, Nov. 23 (HealthDay News) -- Biofilms of Escherichia coli bacteria can form on urethral catheters within hours, but the process can be delayed for a few days by using antibiotics, according to research published in the November issue of Urology.
Abstract
Full Text (subscription or payment may be required)
Kidney Disease Patients Referred Late for Transplant
MONDAY, Nov. 20 (HealthDay News) -- Chronic kidney disease is becoming more prevalent and up to 64 percent of cases are referred late for renal replacement therapy, according to a review published in the November issue of the Mayo Clinic Proceedings.
Abstract
Full Text (subscription or payment may be required)
Editorial
AACR: Obesity Raises Prostate Cancer Death Risk
FRIDAY, Nov. 17 (HealthDay News) -- Among men who develop prostate cancer, those who are obese or overweight have a higher risk of dying from the disease, according to a study presented at the American Association for Cancer Research's Frontiers in Cancer Prevention Research meeting, held in Boston.
More Information
Drug Combination Helps Men with Overactive Bladder
WEDNESDAY, Nov. 15 (HealthDay News) -- A combination of extended-release tolterodine and tamsulosin appears to be safe and effective in treating men with overactive bladder, according to a randomized, industry-funded trial reported in the Nov. 15 issue of the Journal of the American Medical Association.
Abstract
Full Text
Prostate-Specific Antigen Test Overused in Elderly Men
TUESDAY, Nov. 14 (HealthDay News) -- Despite guidelines suggesting the test does elderly patients more harm than good, U.S. physicians routinely perform prostate-specific antigen (PSA) screenings on males over 70, according to a report in the Nov. 15 Journal of the American Medical Association. The findings were presented Nov. 14 at a special American Medical Association men's health news briefing in New York City.
Abstract
Full Text (subscription or payment may be required)
Editorial
Six-Month Testosterone Therapy May Not Affect Prostate
TUESDAY, Nov. 14 (HealthDay News) -- Six months of testosterone replacement therapy (TRT) normalizes serum androgen levels in older men with late-onset hypogonadism while having little effect on prostate tissue, according to a report in the Nov. 15 Journal of the American Medical Association. The findings were announced Nov. 14 at a special American Medical Association men's health briefing in New York City.
Abstract
Full Text (subscription or payment may be required)
Adjuvant Radiotherapy May Fight Advanced Prostate Cancer
TUESDAY, Nov. 14 (HealthDay News) -- A 10-year randomized, prospective clinical trial may provide guidance on the use of adjuvant radiotherapy after radical prostatectomy in men with pathologically advanced prostate cancer. The study, published in the Nov. 15 issue of the Journal of the American Medical Association, found the treatment could reduce prostate-specific antigen relapse and disease recurrence, but not overall patient survival.
Abstract
Full Text (subscription or payment may be required)
Gene Identified for Early Onset Nephrotic Syndrome
THURSDAY, Nov. 9 (HealthDay News) -- Researchers have identified a gene that when mutated can cause early onset nephrotic syndrome, a defect of the kidney glomerular filter that can lead to end-stage kidney disease, according to a study published online Nov. 5 in Nature Genetics.
Abstract
Full Text (subscription or payment may be required)
Human Stem Cells Lower Blood Glucose in Diabetic Mice
THURSDAY, Nov. 9 (HealthDay News) -- Human stem cells from bone marrow can lower blood glucose and boost the secretion of mouse insulin in diabetic mice, according to a report published online Nov. 6 in the Proceedings of the National Academy of Sciences.
Abstract
Full Text
Kidney Transplant Induction Therapies Compared
WEDNESDAY, Nov. 8 (HealthDay News) -- In patients who receive kidney transplants from deceased donors, induction therapy with antithymocyte globulin reduces the incidence and severity of acute rejection compared to basiliximab, but not the incidence of delayed graft function, according to a report in the Nov. 9 issue of the New England Journal of Medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial
ASTRO: Extra Hormone Therapy Benefits Prostate Cancer
TUESDAY, Nov. 7 (HealthDay News) -- An additional 24 months of hormone treatment after radiation improves survival in men with aggressive prostate cancer, according to a study presented at the annual meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.
Abstract
Radiation Delay Does Not Affect Prostate Cancer Relapse
FRIDAY, Nov. 3 (HealthDay News) -- Delaying radiotherapy for prostate cancer more than 40 days after the initial consultation has no significant effect on biochemical relapse rates, according to study results published in the October issue of the American Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Pelvic Radiation Doesn't Benefit All Prostate Cancer Patients
FRIDAY, Nov. 3 (HealthDay News) -- The addition of pelvic radiation to high-dose radiation to the prostate does not improve outcomes for prostate cancer patients with a greater than 15 percent risk of positive pelvic lymph nodes, according to study findings published in the October issue of the American Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
PSA Velocity Predicts Prostate Cancer Outcomes
WEDNESDAY, Nov. 1 (HealthDay News) -- Prostate-specific antigen (PSA) velocity, the rate at which PSA increases or decreases, predicts survival in men who later develop prostate cancer, according to a study published in the Nov. 1 issue of the Journal of the National Cancer Institute.
Abstract
Full Text (subscription or payment may be required)
Editorial
Study Highlights Diversity in Sexual Behavior Across Globe
WEDNESDAY, Nov. 1 (HealthDay News) -- Contrary to popular belief, there is not a trend toward earlier sexual intercourse across the globe, according to the results of a new study of sexual behavior in 59 countries that appears in a special online issue of The Lancet.
Abstract
Full Text (subscription or payment may be required)
